Protagenic Therapeutics, Inc.\new Proceeds from Sale of Available-for-sale Securities
Protagenic Therapeutics, Inc.\new (PTIX) reported Proceeds from Sale of Available-for-sale Securities of $250.00 thousand for the 12-month period ending 2019-12-31, per its 10-K filed 2021-03-25.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleOfAvailableForSaleSecurities · last filed 2021-03-25
- Protagenic Therapeutics, Inc.\new proceeds from sale of available-for-sale securities for the quarter ending 2019-12-31 was $0.00, a 100.00% decline year-over-year.
- Protagenic Therapeutics, Inc.\new proceeds from sale of available-for-sale securities for the quarter ending 2019-09-30 was $0.00, a 100.00% decline year-over-year.
- Protagenic Therapeutics, Inc.\new proceeds from sale of available-for-sale securities for the quarter ending 2019-06-30 was $0.00, a 100.00% decline year-over-year.
- Protagenic Therapeutics, Inc.\new proceeds from sale of available-for-sale securities for the quarter ending 2019-03-31 was $250.00K, a 84.71% decline year-over-year.
- Protagenic Therapeutics, Inc.\new proceeds from sale of available-for-sale securities for fiscal 2019 was $250.00K, a 93.40% decline from fiscal 2018.
- Protagenic Therapeutics, Inc.\new proceeds from sale of available-for-sale securities for fiscal 2018 was $3.79M, a 76.69% increase from fiscal 2017.
- Protagenic Therapeutics, Inc.\new proceeds from sale of available-for-sale securities for fiscal 2017 was $2.15M.
| Period end | Proceeds from Sale of Available-for-sale Securities 3 month | Proceeds from Sale of Available-for-sale Securities 6 month | Proceeds from Sale of Available-for-sale Securities 9 month | Proceeds from Sale of Available-for-sale Securities 12 month |
|---|---|---|---|---|
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $0.00 derived: sum of 2 quarters · filed 2021-03-25 | $0.00 derived: sum of 3 quarters · filed 2021-03-25 | $250.00K 10-K · filed 2021-03-25 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-16 | $0.00 derived: sum of 2 quarters · filed 2020-11-16 | $250.00K 10-Q · filed 2020-11-16 | $870.00K derived: sum of 4 quarters · filed 2020-11-16 |
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-14 | $250.00K 10-Q · filed 2020-08-14 | $870.00K derived: sum of 3 quarters · filed 2020-08-14 | $1.82M derived: sum of 4 quarters · filed 2020-08-14 |
| 2019-03-31 | $250.00K 10-Q · filed 2020-06-18 | $870.00K derived: sum of 2 quarters · filed 2020-06-18 | $1.82M derived: sum of 3 quarters · filed 2020-06-18 | $2.40M derived: sum of 4 quarters · filed 2020-06-18 |
| 2018-12-31 | $620.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-04-29 | $1.57M derived: sum of 2 quarters · filed 2020-04-29 | $2.15M derived: sum of 3 quarters · filed 2020-04-29 | $3.79M 10-K · filed 2020-04-29 |
| 2018-09-30 | $950.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | $1.53M derived: sum of 2 quarters · filed 2019-11-14 | $3.17M 10-Q · filed 2019-11-14 | $3.62M derived: sum of 4 quarters · filed 2019-11-14 |
| 2018-06-30 | $585.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | $2.22M 10-Q · filed 2019-08-14 | $2.67M derived: sum of 3 quarters · filed 2019-08-14 | $3.65M derived: sum of 4 quarters · filed 2019-08-14 |
| 2018-03-31 | $1.64M 10-Q · filed 2019-05-16 | $2.08M derived: sum of 2 quarters · filed 2019-05-16 | $3.06M derived: sum of 3 quarters · filed 2019-05-16 | |
| 2017-12-31 | $450.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-29 | $1.43M derived: sum of 2 quarters · filed 2019-03-29 | $2.15M 10-K · filed 2019-03-29 | |
| 2017-09-30 | $975.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $1.70M 10-Q · filed 2018-11-08 | ||
| 2017-06-30 | $720.00K 10-Q · filed 2018-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| Rafael Holdings, Inc. (RFL) | United States | $0.000B | -0.00 |